EPCCS 2019 Read impressions of the updates on stroke prevention in AF, hypertension, HF and CV risk in diabetes, with emphasis on challenges faced in patients with multimorbidities.
Profs. McManus and Hobbs consider the latest recommendations and insights on how to diagnose elevated blood pressure and when to initiate treatment.
EPCCS 2019 Slides prepared and presented by prof. Richard McManus - Oxford, UK, here offered as an educational service.
ACC 2019 The randomized INFINITY trial showed a reduction in accrual of subcortical white matter disease in older people treated to 130 vs. 145 mmHg, but that did not improve mobility and cognitive function.
The AHA has published a scientific statement on blood pressure measurements in humans to update findings released in the 2005 version.
A study with representative US citizens showed similar trends for most CV risk factors between men and women from 2001 to 2016, with the exception of BMI and total cholesterol, and sex differences for control of hypertension, diabetes and dyslipidemia.
Bryan Williams, co-chair of the 2018 ESC/ESH Hypertension Guidelines, lists the most important new recommendations. Furthermore, he comments on the discussion on differences between the European and American recommendations.
Learn more about the activities of EPCCS that are aimed at supporting primary care professionals manage their patients with cardiovascular and cardiometabolic disease.
Individuals without the 3 common shared risk factors hypertension, overweight and smoking had a delay of 9 years in the onset of disease and gain of 6 years in life expectancy compared to those with these 3 risk factors.
Neil Poulter stresses that, although high BP is considered a boring topic by some, it is crucial to be aware of it before it can be treated properly. You too can get involved in raising awareness.
In SPRINT MIND, no reduction was seen in probable dementia, after a median of 5 years of follow-up and 3.3 years of intervention, but mild cognitive impairment was reduced in the intensively treated arm.
In an analysis of the PARADIGM-HF and ATMOSPHERE trials with HFrEF patients, women showed lower rates of HF hospitalization and CV mortality, however, they had more symptoms and lower HRQL, and appeared undertreated, compared to men.